The price of Inari Medical Inc. (NASDAQ: NARI) closed at $63.17 in the last session, up 6.85% from day before closing price of $59.12. On the day, 1224013 shares were traded. NARI stock price reached its highest trading level at $63.37 during the session, while it also had its lowest trading level at $59.57.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
We take a closer look at NARI’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.90 and its Current Ratio is at 7.50. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on October 12, 2022, initiated with a Buy rating and assigned the stock a target price of $88.
On September 29, 2022, Berenberg started tracking the stock assigning a Buy rating and target price of $85.
On September 13, 2022, Truist started tracking the stock assigning a Hold rating and target price of $87.Truist initiated its Hold rating on September 13, 2022, with a $87 target price.
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 14 when Hoffman William sold 5,000 shares for $60.10 per share. The transaction valued at 300,500 led to the insider holds 1,252,540 shares of the business.
Hill, Mitch C. sold 12,750 shares of NARI for $747,585 on Mar 13. The Chief Financial Officer now owns 187,035 shares after completing the transaction at $58.63 per share. On Feb 27, another insider, Tu Thomas, who serves as the Chief Medical Officer of the company, sold 10,000 shares for $56.72 each. As a result, the insider received 567,219 and left with 107,112 shares of the company.
For the stock, the TTM Price-to-Sale (P/S) ratio is 9.15 while its Price-to-Book (P/B) ratio in mrq is 8.13.
Stock Price History:
Over the past 52 weeks, NARI has reached a high of $95.39, while it has fallen to a 52-week low of $50.50. The 50-Day Moving Average of the stock is 59.33, while the 200-Day Moving Average is calculated to be 69.05.
According to the various share statistics, NARI traded on average about 824.03K shares per day over the past 3-months and 895.9k shares per day over the past 10 days. A total of 53.69M shares are outstanding, with a floating share count of 45.93M. Insiders hold about 1.40% of the company’s shares, while institutions hold 92.70% stake in the company. Shares short for NARI as of Jan 12, 2023 were 2.89M with a Short Ratio of 2.70M, compared to 3.08M on Dec 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 5.39% and a Short% of Float of 5.97%.
The company has 8 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.17 for the current quarter, with a high estimate of -$0.16 and a low estimate of -$0.18, while EPS last year was $0.02. The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.07 and low estimates of -$0.21.
Analysts are recommending an EPS of between -$0.59 and -$0.63 for the fiscal current year, implying an average EPS of -$0.61. EPS for the following year is -$0.29, with 8 analysts recommending between -$0.12 and -$0.56.
According to 7 analysts, the current quarter’s revenue is expected to be $103.77M. It ranges from a high estimate of $107.6M to a low estimate of $98.2M. As of the current estimate, Inari Medical Inc.’s year-ago sales were $83.22M, an estimated increase of 24.70% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $103.88M, an increase of 19.70% less than the figure of $24.70% in the same quarter last year. There is a high estimate of $111.12M for the next quarter, whereas the lowest estimate is $99.6M.
A total of 8 analysts have provided revenue estimates for NARI’s current fiscal year. The highest revenue estimate was $383.3M, while the lowest revenue estimate was $373.9M, resulting in an average revenue estimate of $378.81M. In the same quarter a year ago, actual revenue was $276.98M, up 36.80% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $462.63M in the next fiscal year. The high estimate is $478.9M and the low estimate is $444.6M. The average revenue growth estimate for next year is up 22.10% from the average revenue estimate for this year.